Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort

Adam Hampshire, a, An Doris A. Chatfield b, Anne Manktelow MPhil b, Amy Jolly a, William Trender a, Peter J. Hellyer a, Martina Del Giovane b, Virginia F.J. Newcombe b, Joanne G. Outtrim b, Ben Warne b, Junaid Bhatti b, Linda Pointon b, Anne Elmer e, Nyarie Sithole b, f, John Bradley b, g, h, Nathalie Kingston I, Stephen J. Sawcer I, Edward T. Bullmore c, d, j, James B. Rowe c, d, i and David K. Menon b, c, k, l the Cambridge NeuroCOVID Group, the NIHR COVID-19 BioResource, and Cambridge NIHR Clinical Research Facility

a UK DRI Care Research and Technology Centre, Department of Brain Sciences, Imperial College London, United Kingdom
b Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom
c Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, United Kingdom
d Department of Psychiatry, University of Cambridge, United Kingdom
e National Institute for Health Research Cambridge Clinical Research Facility, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom
f Division of Infectious Diseases, Department of Medicine, University of Cambridge, United Kingdom
g Department of Medicine, University of Cambridge, United Kingdom
h National Institute for Health Research Cambridge BioResource, United Kingdom
i Department of Clinical Neurosciences, and Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom
j Cambridgeshire and Peterborough National Health Service Foundation Trust, United Kingdom
k Division of Anaesthesia, Department of Medicine, University of Cambridge,
l National Institute for Health Research COVID-19 BioResource, United Kingdom

Summary

Background Preliminary evidence has highlighted a possible association between severe COVID-19 and persistent cognitive deficits. Further research is required to confirm this association, determine whether cognitive deficits relate to clinical features from the acute phase or to mental health status at the point of assessment, and quantify rate of recovery.

Methods 46 individuals who received critical care for COVID-19 at Addenbrooke’s hospital between 10th March 2020 and 31st July 2020 (16 mechanically ventilated) underwent detailed computerised cognitive assessment alongside scales measuring anxiety, depression and post-traumatic stress disorder under supervised conditions at a mean follow up of 6.0 (± 2.1) months following acute illness. Patient and matched control (N = 460) performances were transformed into standard deviation from expected scores, accounting for age and demographic factors using N = 66,008 normative datasets. Global accuracy and response time composites were calculated (G_SScore & G_RT). Linear modelling predicted composite score deficits from acute severity, mental-health status at assessment, and time from hospital admission. The pattern of deficits across tasks was qualitatively compared with normal age-related decline, and early-stage dementia.

Findings COVID-19 survivors were less accurate (G_SScore=-0.53SDs) and slower (G_RT=+0.89SDs) in their responses than expected compared to their matched controls. Acute illness, but not chronic mental health, significantly predicted cognitive deviation from expected scores (G_SScore (p=0.0037) and G_RT (p = 0.0366)). The most prominent task associations with COVID-19 were for higher cognition and processing speed, which was qualitatively distinct from the profiles of normal ageing and dementia and similar in magnitude to the effects of ageing between 50 and 70 years of age. A trend towards reduced deficits with time from illness (r~0.15) did not reach statistical significance.

DOI of original article: http://dx.doi.org/10.1016/j.eclinm.2022.101552

*Corresponding author at: UK DRI Care Research and Technology Centre, Department of Brain Sciences, Imperial College London, 926, Sir Michael Uren Hub, 86 Wood Lane, London W12 0BZ, United Kingdom.
**Corresponding author at: Division of Anaesthesia, University of Cambridge, Box 93, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK.

E-mail addresses: a.hampshire@ic.ac.uk (A. Hampshire), dkm13@cam.ac.uk (D.K. Menon).

Present address: Division of Anaesthesia, University of Cambridge, Box 93, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK.
Interpretation Cognitive deficits after severe COVID-19 relate most strongly to acute illness severity, persist long into the chronic phase, and recover slowly if at all, with a characteristic profile highlighting higher cognitive functions and processing speed.

Funding This work was funded by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC), NIHR Cambridge Clinical Research Facility (BRC-1215-20014), the Addenbrooke’s Charities Trust and NIHR COVID-19 BioResource RG9402. AH is funded by the UK Dementia Research Institute Care Research and Technology Centre and Imperial College London Biomedical Research Centre. ETB and DKM are supported by NIHR Senior Investigator awards. JBR is supported by the Wellcome Trust (220258) and Medical Research Council (SUAG/051 G101400). VFJN is funded by an Academy of Medical Sciences/ The Health Foundation Clinician Scientist Fellowship. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Copyright © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Keywords: COVID-19; Cognition; Cognitive assessment; Attention; Memory; Reasoning; Planning

Research in context

Evidence before this study
A PubMed search for articles using the terms ‘COVID-19’, ‘chronic’ and ‘cognitive impairment’ returns 85 results between 2020 and 2022, reflecting growing concern that people may suffer persistent cognitive problems after SARS-CoV-2 infection. However, most of these studies have built on either subjective report of cognitive problems or brief pen-and-paper assessment scales that lack sensitivity to mild deficits and precision regarding affected cognitive domains.

Added value of this study
Using precision computerised cognitive assessment tools, we observed that 46 COVID-19 patients matched for age, gender, education and first language, 6–10 months after admission for care at Addenbrookes hospital perform less well than controls in terms of cognition. Critically, the scale of their cognitive deficits correlated with acute illness severity as recorded during the hospital stay, but not fatigue or mental health status at the time of cognitive assessment.

Implications of all the available evidence
These results suggest that the patients who have recovered from severe COVID-19 may need longer term support for cognitive deficits that persist into the chronic phase. More research is required to understand the basis of these deficits. Future work will be focused on mapping these cognitive deficits to underlying neural pathologies and inflammatory biomarkers, and to longitudinally track recovery into the chronic phase.

Introduction
There is growing evidence that COVID-19 can cause lasting cognitive and mental health problems. Recovered patients reporting psychological symptoms including fatigue, cognitive difficulties (“brain fog” and “problems finding the words”), sleep disturbances breathlessness and psychiatric disorders months after infection. In the UK alone, 13.7% of 20,000 individuals reported having symptoms inclusive of cognitive difficulties 12 weeks after a positive COVID-19 test (UK Office for National Statistics, April 2021). Mild cases can report persistent cognitive symptoms; however, prevalence is higher in severe cases, with ~33–76% of patients suffering cognitive symptoms 3–6 months post hospitalisation.

The neurobiological and psychological bases of these deficits remain unclear. Imaging biomarker studies indicate multiple likely candidates. Indeed, drawing parallels with serious acute respiratory syndrome (SARS), middle eastern respiratory syndrome (MERS) and post-critical illness/intensive care syndrome, a range of neurological/central nervous system (CNS) complications can arise from infection. Most notably, encephalitis, ischaemia, haemorrhage, microstructural and functional changes and cerebrovascular disease (CVD) have been observed in COVID-19 patients, and more recently, evidence of brainstem inflammation using 7 Tesla magnetic resonance imaging (MRI) has been reported. There has been concern regarding whether cognitive deficits will remain for years as a chronic syndrome, and whether patients who develop CVD as a result of infection will experience neurodegeneration and dementia in the long-term, despite recovery of other acute and sub-acute symptoms.
Key limitations for much of this early work include a reliance on self-report as opposed to objective assessment of cognitive deficits, the application of neuropsychological scales that lack sensitivity to detect subtle deficits in the formerly unimpaired or precision to differentiate deficits across cognitive domains, and uncertainty regarding longevity of deficits. Furthermore, depression, anxiety, fatigue and post-traumatic stress are elevated post COVID-19 illness, 11 which might mediate the association with cognitive sequelae.

Recently, we provided preliminary results addressing some of these limitations. Specifically, we used computerised cognitive assessment technology, 14,15 which has superior sensitivity and precision to gold-standard neuropsychological scales, 14 to investigate objectively measurable deficits across multiple cognitive domains in a large online cohort 15,16 that incidentally included people who reported infection with COVID-19 of varying severity. 17 Higher cognitive functions such as spatial planning and analogical reasoning appeared to be disproportionately impaired, especially in hospitalised patients. However, our earlier analyses lacked clinical-record corroboration of self-reported illness severity or hospital treatment. Furthermore, participants primarily were in the early chronic phase ~2–3 months post illness, which limited insight into the longevity of deficits.

Here, we use the same technology to assess patients at timepoints ranging from between ~1 and 10 months post admission to hospital for severe COVID-19. We sought to determine whether (i) the finding of higher cognitive deficits after COVID-19 infection can be replicated in a hospital confirmed cohort, (ii) the cognitive deficits relate to features of acute illness vs. mood, anxiety, tiredness or post-traumatic stress disorder (PTSD) at the point of assessment, (iii) the deficits negatively correlate with time since illness and (iv) the scale and profile of deficits is qualitatively comparable to that observed in normal age-related decline or dementia.

**Methods**

**Data collection**
All patients admitted to Addenbrookes Hospital with COVID-19 between 10th March 2020 and 31st July 2020, who survived and consented to take part were eligible for this cohort study. This comprised 489 patients, of whom 49 were consented to the NIHR COVID-19 BioResource to participate in the study and were administered the follow up battery. The study was approved by the Cambridge Central Research Ethics Committee (17/EE/0025 0025 & IRAS ID: 220277). Of these, 46 patients (27 females, 19 males, age mean=51 years standard deviation (SD)=14 years, range 28–83 years) completed the study protocol adequately to allow analysis (Tables S1–3). Based on the effect size observed in our previous citizen science dataset, 17 where people were assessed using the same technology, expected effect size for critically ill hospitalised patients would be >0.5 standard deviations. At n=46, power was sufficient to detect with one-tailed alpha at p < 0.05 a 0.5SD effect size difference as gauged by DfE scores from the linear model at 96% relative to zero and at 94% relative to the matched control group. There was statistical power of 95% to detect medium strength correlations of r = 0.50 at two tailed alpha p < 0.05. Participants completed a custom computerised cognitive assessment battery under supervised conditions via the Cognitron platform, 17,18 comprising 8 tasks deployed on an iPad (Supplemental Methods), as well as standard mood, anxiety and post-traumatic stress scales, specifically, the Generalized Anxiety Disorder 7 (GAD-7), 19 the Patient Health Questionnaire 9 (PHQ-9) 20,21 and the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders 5 (PCL-5) 22 in a return visit to the hospital on average 179 days after illness onset (SD=62 interquartile range=81).

**Statistical methods**
All analyses were conducted in MATLAB R2020a. To enable correlation of deficit magnitude with clinical and mental health measures whilst accounting for population variables, accuracy and median reaction times were extracted for each task, comprising 16 measures (Table S4), were transformed to deviation from expected (DfE) scores (see below definition) relative to N = 66,008 normative datasets (Table S5), comprising individuals who had performed the same set of tasks. Specifically, to calculate DfE scores, linear models were trained to predict performance for each task within the normative dataset from age decade, sex (male, female, other), education level, handedness (left, right ambidextrous) and first language (English, other). The trained models were then applied to the patient demographics, to which they were naive, providing expected scores for each individual. DfE score was quantified as the difference between observed minus predicted score divided by the control standard deviation. Non-compliant individuals from the normative dataset already had been identified and removed based on responding unfeasibly fast given the response time distribution; applying the same threshold identified no non-compliant participants within the patient dataset. Four patients could not complete Verbal Analogies and one could not complete Spatial Planning as they found them too challenging. Control and patient datasets were concatenated, and composites were then calculated by taking the first unrotated principal component (Table S6) across the eight summary score measures (G_Sscore), focused on accuracy, and across the eight response time scores (G_RT), focussing on speed of response. Component scores were calculated for each subject via regression of
the component loadings matrix across the above measures, excluding any unavailable datapoints, and transformed to DfE score as described above. For further comparison, a set of matched controls was identified from within the normative database and processed in the same manner as the patients. Specifically, for each patient, ten unique control datasets were randomly selected who exactly matched them in terms of age decade, sex, handedness, first language and education level.

All statistical analyses applied a prior significance cut-off set to $p < 0.05$. T-tests, performed one-tailed with family wise error (FWE) correction for multiple comparisons, evaluated whether patient composite and individual task DfE scores were consistently poorer than expected relative to the matched normative group. Multiple regression determined whether G_SScore and G_RT DfE scores could be predicted from clinical features during the acute hospital stay or mental health measures at the time of assessment. Clinical features were World Health Organisation (WHO) COVID-19 severity score, highest C-reactive protein (CRP), mechanical ventilation, extrapulmonary support, days ventilated, tracheostomy, and highest D-dimer; as well as age, sex and time since illness. Mental health scores were the GAD7, PHQ9 and PCL5. Due to high correlations between some of these clinical features, the feature matrix was reduced by applying Principal Component Analysis with varimax rotation, where the number of components was defined according to the Kaiser convention of retaining components with eigenvalues $>1$. The relationship between G_SScore and G_RT to time since illness was further examined in isolation using bivariate correlations with one-tailed significance.

To qualitatively gauge whether the profile of COVID-19 related cognitive deficits was similar in pattern or scale to age-related decline, standard deviation differences were extracted from the normative models (that is, accounting for the other population variables listed above) for each task between people at ages aged 70–79 minus those 20–50 or 50–59 within the control data-set. For further qualitative comparison, performance data from a previously collected group of 28 early-mid stage dementia patients were submitted to the same DfE pipeline as described above and effect sizes plotted (clinical and demographic details provided in Table S7).

**Results**

T-tests of global summary score and response time composites (Figure 1a) confirmed that participants who had been hospitalised due to COVID-19 scored significantly lower and were slower in their responses than would be expected given the control population as gauged by DfE scores ($G_{SScore}$ estimate=-0.538 SDs, $t=4.214$, $p < 0.0001$; $G_{RT}$ estimate=0.725SDs, $t = 4.507$, $p < 0.0001$). Repeating the analysis for the 43 chronic-phase patients $>90$ days post symptom onset showed a similar result ($G_{SScore}$ estimate=-0.524 SDs, $t=3.875$, $p = 0.0004$; $G_{RT}$ estimate=0.715SDs, $t = 4.194$, $p < 0.0001$). Contrasting the DfE scores directly against 460 precisely matched individuals (Figure 2), 10 per patient, from the control database reinforced this observation (mean difference in $G_{SScore}$ estimate=-0.525SDs, $t=-4.327$, $p < 0.0001$; mean difference in $G_{RT}$ estimate=-0.887SDs, $t = 5.803$, $p < 0.0001$).

Application of Principal Component Analysis to the matrix of clinical and mental health features identified three components with eigenvalues $>1$ capturing 74% of the variance (Figure 1b). After varimax rotation, Component 1 captured variance pertaining to general severity of acute illness, including heavy positive loadings from WHO COVID-19 severity score, highest CRP, and requirement for mechanical ventilation, extrapulmonary organ support and days ventilated, moderate positive loading with age and requirement of tracheostomy and moderate negative loading for days since illness. Component 2 had heavy positive loading of requirement for tracheostomy and days ventilated, moderate positive loading for highest D-dimer and mechanical ventilation and extrapulmonary support, and moderate negative loading for females vs. males and time from illness onset. Component 3 had heavy positive loadings for the three mental health scales.

Multiple regression of the component scores onto DfE performance composites (Figure 1e) showed a significant negative correlation between $G_{SScore}$ and Component 1 (Estimate=-0.346, $F(1,42)=9.392$, $p = 0.00380$), but not Component 2 (Estimate=0.140, $F(1,42)=1.841$, $p = 0.18208$) or Component 3 (Estimate=-0.153, $F(1,42)=1.855$, $p = 0.18041$). There was also a threshold level negative correlation between $G_{RT}$ and Component 1 (Estimate=0.305, $F(1,42)=4.008$, $p = 0.05178$), but not Component 2 (Estimate=-0.177, $F(1,42)=1.791$, $p = 0.21044$) or Component 3 (Estimate=0.111, $F(1,42)=0.592$, $p = 0.46861$).

Bivariate correlations (Table S8) showed significant associations between $G_{SScore}$ and Severity WHO COVID-19 ordinal scale, mechanical ventilation, extrapulmonary organ dysfunction support and highest CRP during admission at the one tailed uncorrected threshold. However, the hypothesised trends towards reduced underperformance over time were of small effect size and were statistically non-significant ($G_{SScore}$ $r = 0.15$).
\[ p = 0.1542, \ G_{-RT} r = -0.16, p = 0.1486 \] one tailed and uncorrected. Reanalysis focusing exclusively on those who were or were not ventilated relative to their respective controls showed significant cognitive deficits in both subgroups (Fig. S1 & Table S9).

Finally, DfE scores were examined at the individual task level. There was a broad pattern of reduced accuracy and slowed response compared to the 460 matched controls (Table 1, Figure 2a), with multiple tasks surviving the \( p < 0.05 \) one-tailed and family wise error (FWE) corrected for multiple comparisons threshold. As predicted, underperformance was more substantial for tasks challenging higher cognitive functions such as Analogical Reasoning (score -0.85SDs RT +1.34SDs) and Spatial Planning (score +0.28SDs RT +0.89SDs), as well as 2D Manipulations (score -0.58SDs RT +0.57SD) and word recall (immediate score -0.43SDs RT +0.43SDs delayed score -0.051SDs RT +0.46SDs).

For comparison (Figure 2), the pattern of mean age-related differences in performance of people in their 70s minus 20s or 70s minus 50s was quite distinct, with age related differences being most pronounced for 2D Manipulations, Spatial Span and Target Detection as opposed to Spatial Planning or Verbal Analogies. Furthermore, the 28 dementia patients who undertook 6 of the tasks showed the greatest DfE score on the Word Memory task with notably higher effect size.

**Discussion**

Individuals who survive severe COVID-19 illness have objectively measurable cognitive deficits, lasting many months, with respect to age- and demographic-adjusted
Taking Cohen’s notion of effect sizes as a gauge, the scale of those deficits was large; on average the $0.52\text{SD}$ and $0.89\text{SD}$ levels of underperformance on global accuracy and response time composite measures span the medium to large effect size range. For individuals who required mechanical ventilation, both composites were in the large range at $0.90\text{SD}$s and $1.0\text{SD}$s, respectively, which is somewhat larger than our previous online study using the same assessment tools. The scale of DfE score for severe COVID-19 survivors was similar in scale to normal age-related decline in cognition between individuals in their seventies when compared to individuals in their fifties (but less than age related decline in cognition between 20 and 70 years of age), and less than cognitive problems in people with dementia 3 years post diagnosis. However, the pattern of deficits across cognitive domains was quite distinct to either of these comparisons. NB dementia patients had not undertaken Spatial Planning or 3D Perspective Rotation. Y axis scale is standard deviation units relative to controls.

**Figure 2. Multivariate profile of cognitive deficits after severe COVID-19 and relationship to age and dementia**

Upper. Patients showed a consistent pattern of cognitive underperformance in terms of reduced accuracy and slowed processing time that varied in magnitude across tasks. $^{*} p < 0.05$, $^{**} p < 0.01$, $^{***} p < 0.001$ one tailed FWE corrected for 18 multiple comparisons. Executive tasks tapping higher cognitive functions showed particularly strong associations, which was qualitatively different to the association with age-related decline or dementia. Y axis scale in standard deviation units relative to controls.

Lower. The scale of DfE score for severe COVID-19 survivors was similar in scale to normal age-related decline in cognition between individuals in their seventies when compared to individuals in their fifties (but less than age related decline in cognition between 20 and 70 years of age), and less than cognitive problems in people with dementia 3 years post diagnosis. However, the pattern of deficits across cognitive domains was quite distinct to either of these comparisons. NB dementia patients had not undertaken Spatial Planning or 3D Perspective Rotation. Y axis scale is standard deviation units relative to controls.
established that people who have recovered from severe COVID-19 illness can have a broad spectrum of symptoms of poor mental health as do those suffering from Long Covid, which could conceivably contribute to both self-perceived and objectively measured cognitive deficits. These include problems with depression, anxiety post-traumatic stress, low motivation, fatigue, low mood, and disturbed sleep. Here, it was clearly the case that acute illness severity was the better predictor of objectively measurable global cognitive deficits during the chronic phase. At the level of individual clinical features, WHO COVID-19 severity score, highest CRP and the requirement for mechanical ventilation and multiple organ support were predictive of poorer cognitive performance.

All patients were recruited from the same hospital and following illness within a narrow timeframe, which given differences in patient treatment and virus variants across time limits our confidence when generalising these results. We believe that this limitation is somewhat mitigated by the concordance between the results presented here and our previous citizen science dataset, published in this journal. Nonetheless, future research should seek to determine the relationship between variants, treatment strategies and cognitive outcomes at larger scale.

Regarding how representative the cohort was, the recruited population were younger, and more frequently female, and with a higher proportion of critical care admissions (WHO Ordinal Scale >6) than those who came through the centre (Tables S10−S14). A significant proportion, though not all, of these differences is attributable to the mortality of 24% in the overall admitted population, since non-survivors were older (median age=80 inter quartile range =73−87), more often male (64%), and may have included patients in whom treatment limitation decisions may have been in place.

Our analysis of fatigue post COVID-19 illness was not in the original analysis plan. However, scores capturing self-report of fatigue in the months post illness were available for 38 patients (Tables S1−3) from the Post-Intensive Care Unit Presentation Screen, a brief functional screening tool to inform the rehabilitation needs after treatment in intensive care settings. 28 of them endorsed some level of fatigue. Fatigue score correlated robustly with the mental health composite score ($r=-0.45$ $p=0.005$) but not with the acute illness composite score ($r=0.03$ $p=0.852$) or either of the cognitive composite scores ($G\_ACC$ $r=0.19$ $p=0.240$; $G\_RT$ $r=-0.16$ $p=0.343$). These results indicate that although both fatigue and mental health are prominent chronic sequelae of COVID-19, their severity is likely to be somewhat independent from the observed cognitive deficits.

A further limitation was that the acute clinical features were too highly correlated with each other to dissociate. All but two of the participants requiring mechanical ventilation also required multiple organ support, and the requirement for mechanical ventilation correlated with highest CRP, a measure of inflammation, at $r\sim0.8$. The observed correlation with a marker of acute inflammation may reflect a causal relationship beyond the severity of respiratory problems; however, given the high correlation to other clinical features of the acute phase, work seeking to disentangle underlying

| Effect size (DfE)                  | t     | p (corrected) |
|-----------------------------------|-------|---------------|
| Accuracy                          |       |               |
| Verbal analogies                  | -0.854| -6.205        | <0.00001     |
| 2D manipulation                   | -0.575| -4.221        | 0.00026      |
| Words immediate                   | -0.432| -2.869        | 0.03863      |
| Spatial span                      | -0.405| -3.605        | 0.00309      |
| Target detection                  | -0.176| -1.450        | 1.32876      |
| 3D rotation                       | -0.076| -0.996        | 2.87946      |
| Words delayed                     | -0.051| -0.458        | 5.82405      |
| Spatial planning                  | 0.283 | 1.510         | 1.18614      |
| Latency                           |       |               |
| Spatial span                      | 0.231 | 1.543         | 1.11135      |
| Words immediate                   | 0.431 | 3.035         | 0.02276      |
| Target detection                  | 0.444 | 2.568         | 0.09468      |
| Words delayed                     | 0.463 | 2.942         | 0.03070      |
| 2D manipulation                   | 0.570 | 3.879         | 0.00107      |
| 3D rotation                       | 0.620 | 3.522         | 0.00421      |
| Spatial planning                  | 0.888 | 4.779         | 0.00002      |
| Verbal analogies                  | 1.337 | 7.018         | <0.00001     |
| Global                            |       |               |
| $G\_SScore$                       | -0.525| -4.327        | 0.00016      |
| $G\_RT$                           | 0.887 | 5.803         | <0.00001     |

Table 1: T-tests contrasting patients vs. 460 matched controls (one-tailed and FWE corrected for multiple comparisons).
clinical causes of the observed cognitive deficits will require either substantial sized cohorts with sufficient power to delineate highly correlated predictors or additional data types, such as brain imaging in order to detect associations with markers in specific types of neuropathology.

Some previous studies have observed significant recovery across time in terms of cognitive symptoms\(^{13}\) and imaging measures of brain function.\(^{13}\) In accordance with these studies, we did observe slow and non-significant trends towards reduced deficits in both accuracy and response latency as a function of time from illness. We conclude that any recovery in cognitive faculties is at best likely to be slow. It also is important to consider that trajectories of cognitive recovery may vary across individuals depending on illness severity and the neurological or psychological underpinnings, which are likely complex. Plotting recovery trajectories and untangling their multivariate relationships to clinical features will require multi-timepoint studies in larger cohorts.

At a finer multivariate grain, the profile of deficits replicates our previous report in an online cohort of disproportionate underperformance within certain cognitive domains. In concordance with a previous large scale online study this pattern includes tasks designed to assess performance accuracy of attention, memory, difficult word-based reasoning and planning.\(^{17}\) However, we also observed slowed processing speed. On a neurological level, this pattern of impairment aligns with the observation of sub-acute phase hypometabolism within frontoparietal systems after COVID-19 illness\(^{26}\) that are known to be recruited in different task sets that are known to be recruited in different task sets toire of disorders, especially populations who have recovered from other critical illnesses, and cross relate these detailed cognitive profiles to imaging and blood biomarker measures of neuropathology and tracking recovery and decline trajectories over a longer temporal scale.

In summary, severe COVID-19 illness is associated with significant objectively measurable cognitive deficits that persist into the chronic phase. The scale of the deficits correlates with clinical severity during the acute phase as opposed to mental health status at the time of assessment, shows at best a slow recovery trajectory and the multivariate profile of deficits is consistent with higher cognitive dysfunction as opposed to accelerated ageing or dementia.

**Funding**

This work was funded by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC), NIHR Cambridge Clinical Research Facility (BRC-1215-20014), the Addenbrooke’s Charities Trust and NIHR COVID-19 BioResource RG9402. AH is funded by the UK Dementia Research Institute Care Research and Technology Centre and Imperial College London Biomedical Research Centre. ETB and DKM are supported by NIHR Senior Investigator awards. JBR is supported by the Wellcome Trust (220238) and Medical Research Council (SUAG/051 G101400). VFJN is funded by an Academy of Medical Sciences/ The Health Foundation Clinician Scientist Fellowship. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

**Contributors**

AH and DKM had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: AH, JB, ETB, JBR, DKM Acquisition, analysis, or interpretation of data: AH, DAC, AM, AJ, WT, PH, MDG, VFJN, JGG, JB, LP, AE, NS, JB, NK, SJ, S, DKM Drafting of the manuscript: AH. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: AH. Obtained funding: JB, JBR, ETB, DKM. Supervision: AH, ETB, JBR, DKM.

**Data sharing statement**

Requests for data should directed to the corresponding authors. Data will be available upon reasonable request.

**Declaration of Interests**

Dr. Hampshire reports grants from UK Dementia Research Institute, grants from NIHR Imperial Biomedical Research Centre, and grants from NIHR, outside the...
submitted work; and is Co-director and owner of H2 Cognitive Designs Ltd and director and owner of Future Cognition Ltd, which support online cognitive studies and develop custom cognitive assessment software, respectively. Ms. Chatfield has nothing to disclose. Ms. Manktelow has nothing to disclose. Dr. Jolly has nothing to disclose. Mr. Warne has nothing to disclose. Ms. Outrim has nothing to disclose. Mr. Warr has nothing to disclose. Dr. Bhatti has nothing to disclose. Ms. Pointon has nothing to declare. Ms. Elmer has nothing to declare. Dr. Sithole has nothing to disclose. Dr. Bradley has nothing to disclose. Ms. Chatfield has nothing to disclose. Ms. Manktelow has nothing to disclose. Trender has nothing to disclose. Dr. Hellyer reports being Chief Executive of H2 Cognitive Designs LTD, which provides a platform for online cognitive tests for remote assessment and receives remuneration for role. Ms. Del Giovane has nothing to disclose. Dr. Newcombe reports grants from Academy of Medical Sciences / The Health Foundation Clinician Scientist Fellowship during the conduct of the study. Ms. Outrim has nothing to disclose. Mr. Warne has nothing to disclose. Dr. Bhatti has nothing to disclose. Ms. Pointon has nothing to declare. Ms. Elmer has nothing to disclose. Dr. Sithole has nothing to disclose. Dr. Bradley has nothing to disclose. Ms. Chatfield has nothing to disclose. Ms. Manktelow has nothing to disclose. Trender has nothing to disclose. Dr. Hellyer reports being Chief Executive of H2 Cognitive Designs LTD, which provides a platform for online cognitive tests for remote assessment and receives remuneration for role. Ms. Del Giovane has nothing to disclose. Dr. Newcombe reports grants from Academy of Medical Sciences / The Health Foundation Clinician Scientist Fellowship during the conduct of the study. Ms. Outrim has nothing to disclose. Mr. Warne has nothing to disclose. Dr. Bhatti has nothing to disclose. Ms. Pointon has nothing to declare. Ms. Elmer has nothing to disclose. Dr. Sithole has nothing to disclose. Dr. Bradley has nothing to disclose. Ms. Chatfield has nothing to disclose. Ms. Manktelow has nothing to disclose. Trender has nothing to disclose. Dr. Hellyer reports being Chief Executive of H2 Cognitive Designs LTD, which provides a platform for online cognitive tests for remote assessment and receives remuneration for role. Ms. Del Giovane has nothing to disclose. Dr. Newcombe reports grants from Academy of Medical Sciences / The Health Foundation Clinician Scientist Fellowship during the conduct of the study. Ms. Outrim has nothing to disclose. Mr. Warne has nothing to disclose. Dr. Bhatti has nothing to disclose. Ms. Pointon has nothing to declare. Ms. Elmer has nothing to disclose. Dr. Sithole has nothing to disclose. Dr. Bradley has nothing to disclose. Ms. Chatfield has nothing to disclose. Ms. Manktelow has nothing to disclose. Trender has nothing to disclose. Dr. Hellyer reports being Chief Executive of H2 Cognitive Designs LTD, which provides a platform for online cognitive tests for remote assessment and receives remuneration for role. Ms. Del Giovane has nothing to disclose. Dr. Newcombe reports grants from Academy of Medical Sciences / The Health Foundation Clinician Scientist Fellowship during the conduct of the study. Ms. Outrim has nothing to disclosure. Dr. Bullmore reports personal fees from GlaxoSmithKline, personal fees from Sosei Heptares, outside the submitted work; and is Honorary Treasurer and member of Council for the Academy of Medical Sciences. Dr. Menon reports grants from Lantmannen AB, other from Inte- fees from Calico LLC, personal fees from GlaxoSmithKline, personal fees from Sosei Heptares, outside the submitted work; and is Honorary Treasurer and member of Council for the Academy of Medical Sciences. Dr. Menon reports grants from Lantmannen AB, grants from GlaxoSmithKline Ltd, personal fees from Calco LLC, personal fees from GlaxoSmithKline Ltd, personal fees from Lantmannen AB, other from Inte- fees from Calico LLC, personal fees from GlaxoSmithKline, personal fees from Sosei Heptares, outside the submitted work; and reports leadership and fiduciary roles for Queens’ College, Cambridge, Intensive Care National Audit and Research Centre, London, and European Brain Injury Consortium.

Acknowledgments
We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi: 10.1016/j.eclinm.2022.101417.

References
1 Nallamothu B, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.
2 Huang D, Lian X, Song F, et al. Clinical features of severe patients infected with 2019 novel coronavirus: a systematic review and meta-analysis. Ann Transl Med. 2020;8(9):176.
3 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
4 Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):176-178.
5 Inoue S, Hatakeyama J, Kondo Y, et al. Post-intensive care syndrome: its pathophysiology, prevention, and future directions. Acute Med Surg. 2019;6(1):233-246.
6 Lam MH, Wing YK, Yu MW, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169(2):2142-2147.
7 Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020;12(1):170.
8 Bougakov D, Podell K, Goldberg E. Multiple neuroinvasive pathways in COVID-19. Mol Neurobiol. 2021;58(1):954-975.
9 Goldberg E, Podell K, Sodickson DK, Fieremans E. The brain after COVID-19: compensatory neurogenesis or persistent neuroinflammation? EclinicalMedicine. 2021;11:100654.
10 Jason LA, Islam MF, Conroy K, et al. COVID-19 symptoms over time: comparing long-haulers to ME/CFS. Fatigue Biomed Health Behav. 2021.
11 Chamberlain SR, Grant JE, Trender W, Hellyer P, Hampshire A. Post-traumatic stress disorder symptoms in COVID-19 survivors: online population survey. BJPsych Open. 2021;1(2):e147.
12 Soreq E, Violante IR, Daws RE, Hampshire A. Neuroimaging evidence for a network sampling theory of individual differences in human intelligence test performance. Nat Commun. 2021;12(1):2072.
13 Hampshire A, Highfield RR, Parkin BL, Owen AM. Fractionating human intelligence. Neuro. 2012;5(6):1225-1237.
14 Brookner H, Williams G, Hampshire A, et al. FLAME: a computerized neuropsychological composite for trials in early dementia. Alzheimers Dement. 2020;26(10):e12098. (Amst).
15 Hampshire A. Great British intelligence test protocol. Research Square. 2020.
16 Hampshire A, Hellyer PJ, Soreq E, et al. Associations between dimensions of behaviour, personality traits, and mental-health during the COVID-19 pandemic in the United Kingdom. Nat Commun. 2021;12(1):14111.
17 Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19. EclinicalMedicine. 2021 100144.
18 Zhao S, Shihata K, Hellyer PJ, et al. Rapid vigilance and episodic memory decrements in COVID-19 survivors. medrxiv 2021.
19 Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.
20 Kroenke K, Spitzer RL, Williams JB, Lowe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345-159.
21 Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA. 1999;282(18):1777–1744.
22 Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28(6):489-498.
23 WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-77.
24 Beaud V, Crottaz-Herbette S, Dunet V, et al. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. 2021;92(5):567–568.
25 Hellmuth J, Barnett TA, Asken BM, et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J Neurol. 2021;288(3):919-925.
26 Hosp JA, Dressing A, Blazhenets G, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021;144(6):2163-2176.
27 Jaywant A, Vanderkind WM, Alexopoulos GS, Friedman CB, Perlis RH, Gunning FM. Frequency and profile of subjective cognitive
deficits in hospitalized patients recovering from COVID-19. *Neuropsychopharmacology*. 2021.

28 Miskowiak KW, Johnsen S, Sattler SM, et al. Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. *Eur Neuropsychopharmacol*. 2021;46:39–48.

29 Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. *EClinicalMedicine*. 2021;31: 100683.

30 Woo MS, Malsy J, Pottiegen J, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. *Brain Commun*. 2020;2(2):fcaa205.

31 Seesel J, Waterboer T, Hippchen T, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. *Clin Infect Dis*. 2021.

32 Whiteside DM, Oleynick V, Holker E, Waldron EJ, Porter J, Kasprzak M. Neurocognitive deficits in severe COVID-19 infection: case series and proposed model. *Clin Neuropsychol*. 2021;35(4):799–818.

33 Blazhenets G, Schroeter N, Bornmann T, et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. *J Nucl Med*. 2021;62(7):910–915.

34 Jolly AE, Scott GT, Sharp DJ, Hampshire AH. Distinct patterns of structural damage underlie working memory and reasoning deficits after traumatic brain injury. *Brain*. 2020;143(4):1158–1176.